Shanghai Microport EP Medtech Co., Ltd has announced that its balloon type cryoablation catheter and cryoablation equipment have been approved for marketing as innovative devices in China. This marks a significant advancement in the treatment of drug-resistant, recurrent, and symptomatic paroxysmal atrial fibrillation, with the devices being the first of their kind in the country.
Advanced Technology for Safer Surgery
The two products are used in conjunction for the treatment process, leveraging target temperature control technology and multi-channel temperature measurement technology. These advanced features allow for precise control of the internal temperature of the balloon during the treatment and achieve surface temperature monitoring, ensuring a safer surgical procedure.
Implications for Atrial Fibrillation Treatment in China
The approval of Microport EP Medtech’s cryoablation devices underscores the company’s commitment to innovation in the field of cardiovascular medicine. The devices’ ability to control and monitor temperature during surgery is a significant step forward in providing safer and more effective treatment options for patients with atrial fibrillation in China.-Fineline Info & Tech
